Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC.
08:46am, Tuesday, 24'th Sep 2024
SAFETY HARBOR, Fla. , Sept. 24, 2024 /PRNewswire/ --- Integrated Ventures Inc. ("Company", "OTCQB: INTV") is pleased to announce that its newly launched subsidiary, MedWell USA, LLC has signed a strat
Life Time to Host Complimentary GLP-1, Weight Loss Livestream Event with Chief Science Officer and Experts September 25
03:25pm, Monday, 23'rd Sep 2024
Educational panel available for free via the Life Time App 6:00-7:30 p.m. CT CHANHASSEN, Minn.
Biotech stock plays outside of GLP-1 weight-loss market
06:35pm, Thursday, 19'th Sep 2024
BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best biotech plays outside of the GLP-1 weight-loss space. The sky-high demand
MELVILLE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innova
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
10:07am, Wednesday, 18'th Sep 2024
Terns Pharmaceuticals recently posted positive results from a clinical trial involving a weight-loss pill. The results looked better than those from a key rival.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform committed to breaking down barriers to safe and affordable healthcare
Northern Tool + Equipment Announces Partnership with Monster Jam®: Includes a Monster Jam Mini Build with Texas High School Students
02:57pm, Tuesday, 17'th Sep 2024
The partnership also makes Northern Tool + Equipment the official hardware retailer of tools and related equipment partner for Monster Jam BURNSVILLE, Minn., Sept. 17, 2024 /PRNewswire/ -- Northern To
- ASC30 is the first and only small molecule GLP-1 receptor (GLP-1R) agonist that can be dosed once-monthly subcutaneously and once-daily orally to treat obesity - ASC30 is two- to threefold more pot
Hims & Hers: Fear Surrounding GLP-1 Provides Another Opportunity
09:32am, Monday, 16'th Sep 2024
Hims & Hers' stock decline after GLP-1 concerns is an overreaction, presenting a strong investment opportunity. Management's consistent outperformance and strategic leadership, including key hires, bo
Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery
10:03am, Friday, 13'th Sep 2024
I reiterate a 'Buy' rating for BDX with a fair value of $265 per share, driven by growth in GLP-1 drug delivery and the acquisition of Edwards Lifesciences' Critical Care. BDX's strong market position
Mag7, AI and GLP-1: Roundhill CEO on the hottest ETFs to watch
02:51pm, Thursday, 12'th Sep 2024
Dave Mazza, Roundhill Investments CEO, joins CNBC's Bob Pisani on “Halftime Report's” “ETF Edge” segment to discuss the firms' three ETFs following the Mag7, AI and GLP-1 themes.
Modular Medical Announces Finalization of Protocol for GLP-1 Personalized Metabolic Therapy Study Utilizing the MODD1 Platform
08:00am, Wednesday, 11'th Sep 2024
-Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024 -Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for peo
Mondelez is trading as if GLP-1 drugs don't exist, says Jim Cramer
08:20pm, Tuesday, 10'th Sep 2024
'Mad Money' host Jim Cramer looks at how Mondelez is dealing with GLP-1 drugs.
Obesity drugs in kindergarten? Novo Nordisk GLP-1 drug works for kids as young as 6, study finds.
06:02pm, Tuesday, 10'th Sep 2024
Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary school, researchers have concluded that a Novo Nordisk obesity drug may be
Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
